Doximity Q4 CY2025 Results Top Revenue Expectations but Guidance Falls Short.

Doximity (DOCS) reported Q4 CY2025 results with revenue up 9.8% YoY to $185.1 million, beating analyst estimates. However, next quarter's revenue guidance of $143.5 million was 5.2% below estimates. Non-GAAP profit of $0.46 per share was 2.9% above estimates. Management cited delayed pharmaceutical industry budgets and increased AI-related infrastructure spending as primary factors behind underwhelming outcomes. Guidance reflects a cautious stance, with expectations for a slow start to 2026.